Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.48 |
| ▸ | SGK1 | O00141 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998293 | 0.96 | TRPV1 (0.48) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1996930 | 0.95 | TRPV1 (0.51) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1998510 | 0.90 | TRPV1 (0.47) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1996983 | 0.89 | TRPV1 (0.48) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1996556 | 0.88 | PPARG (0.50) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1998122 | 0.85 | TRPV1 (0.48) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL2001870 | 0.84 | TRPV1 (0.50) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL1999131 | 0.82 | TRPV1 (0.46) | TRPV1AKR1B1AKR1A1SGK1PPARG | |
| SCHEMBL2030411 | 0.80 | MAPT (0.51) | TRPV1SGK1PPARGCYP3A4GAA | |
| SCHEMBL2005058 | 0.80 | PPARG (0.47) | TRPV1AKR1B1AKR1A1SGK1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1722789-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | Amgen Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1296967-B1 | BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-7041691-B1 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2006-05-09 | — | — | US | disclosed |
| WO-2005086904-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | TULARIK INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC | 2004-09-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| US-6583157-B2 | Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | TRPV1 2002/4885AKR1B1 666/4885AKR1A1 656/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | TRPV1 1803/4885AKR1B1 1571/4885AKR1A1 1940/4885 |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | TRPV1 1349/4885AKR1B1 2202/4885AKR1A1 2695/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | TRPV1 1898/4885AKR1B1 1544/4885AKR1A1 1915/4885 |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | TRPV1 1349/4885AKR1B1 2202/4885AKR1A1 2695/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | TRPV1 1349/4885AKR1B1 2202/4885AKR1A1 2695/4885 |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | PPARD, PPARG, PPARA | TRPV1 1538/4885AKR1B1 1558/4885AKR1A1 2164/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | TRPV1 1412/4885AKR1B1 2314/4885AKR1A1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.